PDF herunterladen
Semin Neurol 2002; 22(1): 041-052
DOI: 10.1055/s-2002-33047
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Misunderstandings, Misperceptions, and Mistakes in the Management of the Inflammatory Myopathies

John T. Kissel
  • Professor and Vice-Chair, Department of Neurology, Ohio State University, Columbus, Ohio
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. August 2002 (online)

    Lizenzen und Reprints

ABSTRACT

Many misconceptions persist concerning fundamental issues related to the idiopathic inflammatory myopathies. Such misconceptions can lead to frank mistakes in the diagnosis and management of these disorders. In some cases, these misperceptions have resulted from overreliance on out-of-date information and ``classic'' articles that are no longer classic! In other instances, misperceptions persist because of the many voids in our understanding of these diseases. This review uses case presentations to highlight important caveats in diagnosing and managing the common idiopathic inflammatory myopathies.

KEYWORDS

Polymyositis - dermatomyositis - inclusion body myositis - immunotherapy

REFERENCES

  • 1 Nash S M, Kissel J T. Inflammatory myopathies. In: Pourmand R, ed. Neuromuscular Diseases: Expert Clinicians Views Woburn: Butterworth-Heinemann 2001 0: 199-226
    Google Scholar
  • 2 Dalakas M C, Karpati G. Inflammatory myopathies. In: Karpati G, Hilton-Jones D, Griggs RC, eds. Disorders of Voluntary Muscle Cambridge: Cambridge University Press 2001 0: 349-373
    Google Scholar
  • 3 Bronner I M, van der Meulen F G M, Hoogendijk J. Polymyositis: a disease entity disputed.  Neurology . 2002;  58 A389
    PubMedGoogle Scholar
  • 4 Yazici Y, Kagen L J. The association of malignancy with myositis.  Curr Op Rheumatol . 2000;  12 498-500
    PubMedGoogle Scholar
  • 5 Hill C L, Zhang Y, Sigurgeirsson B. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.  Lancet . 2001;  357 96-100
    CrossrefPubMedGoogle Scholar
  • 6 Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study.  Ann Int Med . 2001;  134 1087-1095
    PubMedGoogle Scholar
  • 7 Targoff I N. Update on myositis-specific and myositis-associated autoantibodies.  Curr Op Rheumatol . 2000;  12 475-481
    PubMedGoogle Scholar
  • 8 Chad D A. Inflammatory myopathies. In: Katirji B, Kaminski HJ, Preston DC, et al, eds. Neuromuscular Disorders in Clinical Practice {{ERR}}Boston: Butterworth-Heinemann; 2002: 1169-1180
    Google Scholar
  • 9 Arahata K, Ishihara T, Fukunaga H. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses.  Muscle Nerve . 1995;  2 S56-66
    PubMedGoogle Scholar
  • 10 Kissel J T, Lynn J, Rammohan K W. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy.  Neurology . 1993;  43 532-536
    PubMedGoogle Scholar
  • 11 Kissel J T, Burrow K L, Rammohan K W, Mendell J T, and the CIDD Study Group. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy.  Neurology . 1991;  41 667-672
    PubMedGoogle Scholar
  • 12 Kissel J T. Facioscapulohumeral muscular dystrophy.  Sem Neurol . 1999;  19 35-43
    PubMedGoogle Scholar
  • 13 Maselli R A, Richman D P, Wollmann R L. Inflammation at the neuromuscular junction in myasthenia gravis.  Neurology . 1991;  41 1497-1504
    PubMedGoogle Scholar
  • 14 McNally E M, Ly C T, Rosenmann H. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation.  Am J Med Gen . 2000;  91 305-312
    CrossrefPubMedGoogle Scholar
  • 15 Di Blasi C, Mora M, Pareyson D. Partial laminin alpha2 chain deficiency in a patient with myopathy resembling inclusion body myositis.  Ann Neurol . 2000;  47 811-816
    CrossrefPubMedGoogle Scholar
  • 16 Bohan A, Peter J B. Polymyositis and dermatomyositis.  N Engl J Med . 1975;  292 344-407
    CrossrefPubMedGoogle Scholar
  • 17 Oddis C V. Current approach to the treatment of polymyositis and dermatomyositis.  Curr Op Rheumatol . 2000;  12 492-497
    CrossrefPubMedGoogle Scholar
  • 18 Anonymous. 64th ENMC International workshop: therapeutic approaches to dermatomyositis, polymyositis, and inclusion body myositis.  Neuromuscular Disorders . 2001;  11 88-92
    CrossrefPubMedGoogle Scholar
  • 19 Ghate J, Katsambas A, Augerinouw G, Jorizzo J L. A therapeutic update on dermatomyositis/polymyositis.  Int J Dermatol . 2000;  39 8187
    PubMedGoogle Scholar
  • 20 Callen J P. Dermatomyositis.  Lancet . 2000;  355 53-57
    CrossrefPubMedGoogle Scholar
  • 21 Rose M R, Kissel J T, Bickley L S, Griggs R C. Sustained myoglobinuria: the presenting manifestation of dermatomyositis.  Neurology . 1996;  47 119-123
    PubMedGoogle Scholar
  • 22 Cosnes A, Amaudric F, Gherardi R. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids.  Arch Dermatol . 1995;  131 1381-1385
    CrossrefPubMedGoogle Scholar
  • 23 Kissel J T, Halterman R K, Rammohan K W, Mendell J R. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis.  Arch Neurol . 1991;  48 26-30
    PubMedGoogle Scholar
  • 24 Kissel J T, Mendell J R, Rammohan K W. Microvascular deposition of complement membrane attack complex in dermatomyositis.  N Engl J Med . 1986;  314 329-334
    CrossrefPubMedGoogle Scholar
  • 25 Dalakas M C, Illa I, Dambrosia J M. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.  N Engl J Med . 1993;  329 1993-2000
    CrossrefPubMedGoogle Scholar
  • 26 Vencovsky J, Jarosova K, Machacek S. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis.  Scand J Rheumatol . 2000;  29 95-102
    CrossrefPubMedGoogle Scholar
  • 27 Miller F W, Leitman S F, Cronin M E. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.  N Engl J Med . 1992;  326 1380-1384
    CrossrefPubMedGoogle Scholar
  • 28 Levine T D. B cell depletion chemotherapy with Rituxamab for dermatomyositis.  Neurology . 2002;  58 A490
    PubMedGoogle Scholar
  • 29 Boumpas D T, Chrousos G P, Wilder R L, Cupps T R, Balow J E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates.  Ann Int Med . 1993;  119 1198-1208
    CrossrefPubMedGoogle Scholar
  • 30 Coutlakis P, Buckley L M. Glucocorticoid-induced osteoporosis: prevention and treatment.  Bull Rheumatic Dis . 2000;  49 4:1-4
    PubMedGoogle Scholar
  • 31 Alexanerson H, Stenstrom C H, Jenner G, Lundberg I. The safety of a restrictive home exercise program in patients with recent onset active polymyositis or dermatomyositis.  Scand J Rheumatol . 2000;  29 295-301
    CrossrefPubMedGoogle Scholar
  • 32 Badrising U A, Maat-Schieman M, van Duinen G S. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.  Neurology . 2000;  55 1385-1387
    CrossrefPubMedGoogle Scholar
  • 33 Amato A A, Gronseth G S, Jackson C E. Inclusion body myositis: clinical and pathological boundaries.  Ann Neurol . 1996;  40 581-586
    CrossrefPubMedGoogle Scholar
  • 34 Barohn R J, Amato A A. Inclusion body myositis.  Curr Treat Opt Neurol . 2000;  2 7-11
    PubMedGoogle Scholar
  • 35 Peng A, Koffman B M, Malley J D, Dalakas M C. Disease progression in sporadic inclusion body myositis: observations in 78 patients.  Neurology . 2000;  55 296-298
    PubMedGoogle Scholar
  • 36 Hermanns B, Molnar M, Schroder J M. Peripheral neuropathy associated with hereditary and sporadic inclusion body myositis: confirmation by electron microscopy and morphometry.  J Neurol Sci . 2000;  179 92-102
    CrossrefPubMedGoogle Scholar
  • 37 Van der Merulen F M, Hoogendijk J E, Moons K G, Veldman H, Badrising U A, Wokke J H. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis.  Neuromusc Dis . 2001;  11 447-451
    CrossrefPubMedGoogle Scholar
  • 38 Pruitt 2nd N J, Showalter C J, Engel A G. Sporadic inclusion body myositis: counts of different types of abnormal fibers.  Ann Neurol . 1996;  39 139-143
    CrossrefPubMedGoogle Scholar
  • 39 Amemiya K, Granger R P, Dalakas M C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies.  Brain . 2000;  123 2030-2039
    CrossrefPubMedGoogle Scholar
  • 40 Askanas V, Engel W K. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease.  J Neuropathol Exp Neurol . 2001;  60 1-14
    PubMedGoogle Scholar
  • 41 Banwell B L, Engel A G. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis.  Neurology . 2000;  54 1033-1041
    PubMedGoogle Scholar
  • 42 Griggs R C, Askanas V, DiMauro S. Inclusion body myositis and myopathies.  Ann Neurol . 1995;  38 705-713
    CrossrefPubMedGoogle Scholar
  • 43 Dalakas M C, Sekul E A, Cupler E J, Sivakumar K. The efficacy of high-dose intravenous immunoglobulin (IVIg) in patients with inclusion-body myositis.  Neurology . 1997;  48 712-716
    CrossrefPubMedGoogle Scholar
  • 44 Walter M C, Lochmuller H, Toepfer M. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.  J Neurol . 2000;  247 22-28
    CrossrefPubMedGoogle Scholar
  • 45 Dalakas M C, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.  Neurology . 2001;  56 323-327
    CrossrefPubMedGoogle Scholar
  • 46 Spector S A, Lemmer J T, Koffman B M. Safety and efficacy of strength training in patients with inclusion body myositis.  Muscle & Nerve . 1997;  20 1242-1248
    PubMedGoogle Scholar